RELAY THERAPEUTICS INC (RLAY)

Sector: Health Care

    Home/Companies/RLAY/Annual Meeting

2026 Annual Meeting Analysis

RELAY THERAPEUTICS INC · Meeting: June 9, 2026

Policy v1.2medium confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

1

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Class III Directors

1 FOR/1 AGAINST

Against Analysis

✗ AGAINST
Douglas S. Ingramoverboarding: sitting CEO holds 2 or more outside public board seats

Mr. Ingram is the sitting CEO of Sarepta Therapeutics and also serves on the board of Arrowhead Pharmaceuticals — that is two outside public board seats for a sitting CEO, which exceeds the policy limit of one outside seat and triggers an AGAINST vote regardless of his qualifications.

For Analysis

✓ FOR
Claire Mazumdar, Ph.D.

Dr. Mazumdar joined the board in June 2025, less than 24 months ago, so she is fully exempt from the stock performance trigger under policy; she has relevant biotech and oncology operating experience as CEO of Bicara Therapeutics, and no other policy flags apply.

Of the two Class III nominees, Douglas Ingram receives an AGAINST vote solely because he is a sitting public-company CEO (Sarepta Therapeutics) who already sits on one additional outside public board (Arrowhead Pharmaceuticals), reaching the two-seat limit the policy sets for sitting CEOs. Claire Mazumdar is well-qualified and newly joined, so she receives a FOR vote.

Say on Pay

✗ AGAINST

CEO

Sanjiv K. Patel, M.D.

Total Comp

$4,646,454

Prior Support

56%%

prior Say on Pay support below 70% (56% in 2025) with insufficient structural remediationequity awards in 2025 are entirely time-based stock options with no performance conditions — incentive pay is effectively fixed pay disguised as variable paycompany acknowledged stockholder concern about time-based equity but declined to add performance conditions

Last year only 56% of shareholders voted in favor of the pay program — well below the 70% threshold that requires visible remediation under policy. Despite that weak signal, the company chose in 2025 to grant all equity awards as purely time-based stock options with no performance hurdles, meaning executives receive the full value of those awards simply by staying employed regardless of whether the stock goes up or down beyond the exercise price spread. The policy treats incentive awards with no meaningful performance conditions as effectively fixed pay disguised as variable pay, which is a standalone No trigger; combined with the failure to meaningfully address prior low shareholder support, an AGAINST vote is warranted.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

N/A

Audit Fees

N/A

Non-Audit Fees

N/A

The proxy filing does not include an auditor fee table with specific dollar amounts in the text provided, so the non-audit fee ratio cannot be calculated; tenure is also not disclosed in the excerpts provided. Under policy, when tenure cannot be confirmed the tenure trigger does not fire, and without fee data the ratio trigger cannot fire either. Ernst & Young is a Big Four firm appropriate for a $2.3B market-cap company, and no restatements or other concerns are identified, so the default FOR vote applies.

Stockholder Proposals

1 proposal submitted by shareholders

Proposal 4

Approval of Amendment to Our Fourth Amended and Restated Certificate of Incorporation, as Amended, to Increase the Number of Authorized Shares of Common Stock from 300,000,000 to 450,000,000

✓ FOR
Filed by:Board of Directors (management proposal)OtherCharter Amendment
Board recommends: FOR
board-proposed charter amendment; 50% increase in authorized shares

This is a board-proposed amendment to increase the pool of shares the company is allowed to issue — from 300 million to 450 million, a 50% increase. Relay is a clinical-stage biotech with no revenue that will need to raise additional capital to fund its drug development programs, and having adequate authorized shares is standard practice for companies at this stage. The increase does not in itself dilute existing shareholders (new shares must still be issued through a separate board or shareholder action), and the company has disclosed it is well-capitalized but will need runway beyond the current authorized pool to support future financings; there are no unusual governance concerns associated with this routine housekeeping amendment.

Overall Assessment

The 2026 Relay Therapeutics annual meeting presents four proposals: director elections, advisory vote on executive pay, auditor ratification, and a charter amendment to increase authorized shares. The most significant concerns are the overboarding flag on CEO-director nominee Douglas Ingram and the failure to meaningfully reform a pay program that received only 56% shareholder support in 2025, driving AGAINST votes on both Ingram's election and the Say on Pay proposal.

Filing date: April 28, 2026·Policy v1.2·medium confidence

Compensation Peer Group

22 companies disclosed in 2026 proxy filing

ALECAlector, Inc.
ALLOAllogene Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
ARVNArvinas, Inc.
BEAMBeam Therapeutics Inc.
BBIOBridgeBio Pharma, Inc.
COGTCogent Biosciences, Inc.
CRSPCRISPR Therapeutics AG
DNLIDenali Therapeutics, Inc.
EDITEditas Medicine, Inc.
ERASErasca, Inc.
IGMSIGM Biosciences, Inc.
NTLAIntellia Therapeutics, Inc.
IOVAIovance Biotherapeutics, Inc.
KYMRKymera Therapeutics, Inc.
RXRXRecursion Pharmaceuticals, Inc.
SANASana Biotechnology, Inc.
SDGRSchrödinger, Inc.
SWTXSpringWorks Therapeutics, Inc.
TNGXTango Therapeutics, Inc.
VIRVir Biotechnology, Inc.
ZNTLZentalis Pharmaceuticals, Inc.